Xoft and Elekta sign sales development agreement

Under the agreement, Elekta will share identified sales opportunities for the Xoft Axxent Electronic Brachytherapy in the radiation oncology market. This non-exclusive agreement allows Elekta to expand its revenue to include procedures performed outside shielded rooms by partially sharing in revenues Xoft receives from the sale of the Electronic Brachytherapy controller.

Additionally, the companies will explore other areas of collaboration, which could include international sales and joint development agreements.

Michael Klein, president and CEO of Xoft, said: “Xoft’s expansion into new treatment areas, which are pending FDA clearance, will extend the use of the electronic brachytherapy to endometrial and rectal indications and therefore allow for broader sales opportunities working with Elekta.”